But deciding if it's a good buy takes a little more looking.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

IBB ETF analysis: hold rating as biotech consolidates near highs. Fair 19x P/E, low EPS growth and weak seasonality shape ...

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing ...

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...